Table III.
Specific treatment-related adverse events.
| Adverse event, grade | FOLFOX, n=87 (%) | EOX, n=26 (%) | t/χ2 | P-value |
|---|---|---|---|---|
| Neutropenia | ||||
| 0 | 20 (23) | 6 (23.1) | 1.708 | 0.635 |
| I | 25 (28.7) | 7 (26.9) | ||
| II | 38 (43.7) | 10 (38.5) | ||
| III | 4 (4.6) | 3 (11.5) | ||
| Anemia | 0.099 | 0.952 | ||
| 0 | 41 (47.1) | 13 (50) | ||
| I | 27 (31) | 8 (30.8) | ||
| II | 19 (21.8) | 5 (19.2) | ||
| Thrombocytopenia | 0.326 | 0.850 | ||
| 0 | 77 (88.5) | 23 (88.5) | ||
| I | 9 (10.3) | 3 (11.5) | ||
| II | 1 (1.1) | 0 (0) | ||
| Nausea and vomiting | 10.812 | 0.029 | ||
| 0 | 1 (1.1) | 0 (0) | ||
| I | 15 (17.2) | 5 (19.2) | ||
| II | 53 (60.9) | 13 (50) | ||
| III | 18 (20.7) | 5 (19.2) | ||
| IV | 0 (0) | 3 (11.5) | ||
| Peripheral neuropathy | 1.601 | 0.449 | ||
| 0 | 53 (60.9) | 15 (57.7) | ||
| I | 25 (28.7) | 10 (38.5) | ||
| II | 9 (10.3) | 1 (3.8) | ||
| Hand-foot syndrome | 4.237 | 0.040 | ||
| 0 | 73 (83.9) | 17 (65.4) | ||
| I | 14 (16.1) | 9 (34.6) | ||
| ALT/AST increase | 0.001 | 0.980 | ||
| 0 | 60 (69) | 18 (69.2) | ||
| I | 27 (31) | 8 (30.8) | ||
ALT, alanine transferase; AST, aspartate transferase.